A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.

Yuxian Bai,Jianming Xu,Hui-Chuan Sun,Chunmei Bai,Ru Jia,Yi Li,Wenjie Zhang,Lei Liu,Cheng Huang,Mei Guan,Jinghong Zhou,Weiguo Su

A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.

2021

Yuxian Bai
Jianming Xu
Hui-Chuan Sun
Chunmei Bai
Ru Jia
Yi Li
Wenjie Zhang
Lei Liu
Cheng Huang
Mei Guan
Jinghong Zhou
Weiguo Su

e16123Background: Several clinical studies of vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) therapy as second-line treatment for biliary tract cancer (...

Keywords:

in patient
VEGF receptors
Cancer research
Vascular endothelial growth factor
biliary tract cancer
Medicine
open label
Vascular Endothelial Growth Factor Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations